READ: ARW ON RNA

  1. Mapping The LNP Frontier: The Quest For Better LNPs 3/17/2026

    Having previously served as the head of delivery sciences for Moderna pre-pandemic, Almarsson was part of the RNA-LNP delivery journey long before it was scientifically en vogue. That’s why I was excited to sit down with him to discuss the latest and greatest advancements in the RNA-LNP space. Here, we take stock of the developments he’s been watching in the passive and active delivery spaces.

  2. Sticks, Carrots, & Carolina Reapers: Fact-Checking The "Death" Of The US mRNA Industry 3/16/2026

    Welcome to Advancing RNA’s mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist. Here, in episode 6, our Hot Takes "Season Finale," Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo and Entrée Bio's Michelle Lynn Hall to answer yet another loaded question: Are things in the U.S. for mRNA as bad as they truly seem?

  3. Inside Alnylam's Playbook For High Volume siRNA Production 3/10/2026

    As one of the first companies to establish a chemoenzymatic ligation platform, Alnylam's Maines and Nechev are in the perfect position to espouse wisdom on the practical aspects and remaining challenges of implementing enzymatic ligation at a large scale. Here in this installment, Maines and Nechev outline what they’ve learned thus far about the science of enzymatic ligation, while also paying credence to the unknowns and existing barriers that, as a frontrunner, Alnylam will inevitably (but willingly) be tasked with facing in the future.

  4. mRNA Hot Takes: Ghost Peppers & Global R&D 3/9/2026

    Welcome to Advancing RNA’s mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist. Here, in episode 5, Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo and Entrée Bio's Michelle Lynn Hall to answer the (loaded) question: To do good science in the mRNA sector, should we be staying in the US?

  5. The "Middle Ground" Advantage: Why Alnylam Is Betting Big On Chemoenzymatic Ligation 3/3/2026

    Though conversations are picking up around this hybrid approach, we aren’t exactly known as an industry that embraces risk no-holds barred. While there are a handful of manufacturers and CDMOs who are embracing the hybrid model today, there are many more that are likely to hold out for the next-next gen approach: Fully enzymatic oligo production. However, as Alynlam’s CTO and Chief Quality Officer Tim Maines argued, embarking into the “middle ground” of enzymatic ligation is essential for garnering the step-by-step learnings needed to help us unlock even bigger manufacturing wins in the future. 

  6. mRNA Hot Takes: Habaneros & Headwinds 3/2/2026

    Welcome to Advancing RNA’s mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist. Here, in episode 4, Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo, Entrée Bio's Michelle Lynn Hall, & special guest star Andrew Fraley, founding & managing partner, Sunrise BioVentures, to discuss the industry's biggest missteps and how they've impacted the industry thus far. Topics discussed include the CMC morass, dealmaking nuances, educational initiatives, and more!

  7. The Trough Of Disillusionment: 2026 RNA Reality Checks 2/23/2026

    Welcome to Advancing RNA’s mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist. Here, in episode 3, Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo and Entrée Bio's Michelle Lynn Hall to call out the "hyped" and "not hyped enough" topics of conversation for the RNA space in 2026.

  8. mRNA Hot Takes: Fighting Complacency And "Alternative Facts" In 2026 2/16/2026

    Welcome to Advancing RNA’s mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist. Here, in episode 2, Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo and Entrée Bio's Michelle Lynn Hall to learn their wishlists of much-needed RNA developments for 2026 and to hear their take on an edited quote by Oscar Wilde: “The mRNA industry can survive everything but…?”

  9. The Monster Under The Bed: Defining Potency in the mRNA Space 2/13/2026

    During the CASSS mRNA Symposium last spring, a seemingly simple, straightforward question was raised: How are we defining and measuring our product’s potency? But as we already know, this is far from a straightforward question — and, dear reader, based on the resulting discussion amongst regulators and panel members, it became clear we have a lot of different definitions on what potency even is in the mRNA space.

  10. mRNA Hot Takes: Building A Solid Foundation For Your RNA Company & Products 2/9/2026

    Welcome to Advancing RNA's mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist. Here, in episode 1, Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo and Entrée Bio's Michelle Lynn Hall to discuss the biggest mistakes that can be made in building an mRNA therapeutics company, and much, much more.